Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $18M (up 85.2% year over year) with net income of $2M.
Q2 2026 key financials · XBRL
- Revenue
- $18M
- +85.2% YoY · +18.3% QoQ
- Net income
- $2M
- +162.6% YoY · +881.6% QoQ
- Operating margin
- 9.7%
- EPS (diluted)
- $0.05
- +141.7% YoY · +400.0% QoQ
Source: XBRL data from the FENNEC PHARMACEUTICALS INC. (FENC) Q2 2026 10-Q on SEC EDGAR. USD.
FENNEC PHARMACEUTICALS INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $17.874M vs $9.652M YoY, up $8.222M
- Operating margin 9.7% vs (28.3%) YoY, with operating income $1.737M vs loss $2.732M
- PEDMARK sales $17.164M vs $9.652M, while other revenue contributed $710K
- Cash $41.249M vs $36.788M at December 31, 2025, up $4.461M
- Six-month operating cash flow $2.429M vs $(8.004)M, with financing cash flow $2.032M, including option exercises
Risk Factors
- No Risk Factors section provided in the excerpt
- No newly added, updated, regulatory, operational, competitive, or financial risks identifiable
- Insider trading arrangements: CFO disposition plan covers up to 75,000 shares through September 30, 2026
- Director disposition plan covers up to 55,545 shares through June 25, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FENNEC PHARMACEUTICALS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.